Hyperinsulinism in tyrosinaemia type I

被引:39
|
作者
Baumann, U
Preece, MA
Green, A
Kelly, DA
McKiernan, PJ
机构
[1] Birmingham Childrens Hosp, Liver Unit, Birmingham, W Midlands, England
[2] Birmingham Childrens Hosp, Dept Clin Chem, Birmingham, W Midlands, England
关键词
D O I
10.1007/s10545-005-5517-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Tyrosinaemia type I (TT I) (McKusick 276700) is a heterogeneous disorder with a broad spectrum of clinical phenotypes. Although histological abnormalities of the pancreas are well recognized, there are only incidental reports of pancreatic dysfunction manifested as insulin-dependent diabetes mellitus. We report three subjects with TT I and acute liver dysfunction who had hyperinsulinism in early infancy. Hypoglycaemia persisted despite dietary treatment and one patient had inadequate lipolysis at the time of hypoglycaemia. All three patients were successfully treated with diazoxide (10 mg/kg per day) and chlorthiazide (35 mg/kg per day) and treatment was gradually withdrawn after 9, 13 and 34 months, respectively. The mechanism of pancreatic dysfunction in TT I is unknown but may be related to the toxic metabolites that accumulate in this condition. We conclude that hyperinsulinism is not a rare complication in TT I. In patients with persistent hypoglycaemia, C-peptide should always be measured. Treatment with diazoxide and chlorthiazide is highly effective, appears to be safe, and does not need to be continued lifelong.
引用
收藏
页码:131 / 135
页数:5
相关论文
共 50 条
  • [41] Tyrosinaemia type I - de novo mutation in liver tissue suppressing an inborn splicing defect
    Bliksrud, YT
    Brodtkorb, E
    Andresen, PA
    van den Berg, IET
    Kvittingen, EA
    JOURNAL OF MOLECULAR MEDICINE-JMM, 2005, 83 (05): : 406 - 410
  • [42] COST OF TYROSINAEMIA TYPE ONE IN POLAND IN 2006
    Chrzanowski, M.
    Czech, M.
    Hermanowski, T.
    Sykut-Cegielska, J.
    VALUE IN HEALTH, 2008, 11 (06) : A637 - A637
  • [43] Tyrosinaemia type I—de novo mutation in liver tissue suppressing an inborn splicing defect
    Y. T. Bliksrud
    E. Brodtkorb
    P. A. Andresen
    I. E. T. van den Berg
    E. A. Kvittingen
    Journal of Molecular Medicine, 2005, 83 : 406 - 410
  • [44] Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I
    Overturf, K
    AlDhalimy, M
    Tanguay, R
    Brantly, M
    Ou, CN
    Finegold, M
    Grompe, M
    NATURE GENETICS, 1996, 12 (03) : 266 - 273
  • [45] Hereditary tyrosinaemia type I in Norway: Incidence and three novel small deletions in the fumarylacetoacetase gene
    Bliksrud, Yngve T.
    Brodtkorb, Else
    Backe, Paul H.
    Woldseth, Berit
    Rootwelt, Helge
    SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 2012, 72 (05): : 369 - 373
  • [46] Reversibility of cirrhotic regenerative liver nodules upon NTBC treatment in a child with tyrosinaemia type I
    Crone, J
    Möslinger, D
    Bodamer, OA
    Schima, W
    Huber, WD
    Holme, E
    Ipsiroglu, SS
    ACTA PAEDIATRICA, 2003, 92 (05) : 625 - 628
  • [47] Physical Growth of Patients with Hereditary Tyrosinaemia Type I: A Single-Centre Retrospective Study
    Yilmaz, Ozlem
    Daly, Anne
    Pinto, Alex
    Ashmore, Catherine
    Evans, Sharon
    Gupte, Girish
    Jackson, Richard
    Yabanci Ayhan, Nurcan
    MacDonald, Anita
    NUTRIENTS, 2021, 13 (09)
  • [48] SUCCESSFUL BREAST FEEDING IN TYROSINAEMIA TYPE 1
    Daly, A.
    MacDonald, A.
    Preece, M. A.
    Hendriksz, C.
    Chakrapani, A.
    McKiernan, P.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2005, 28 : 45 - 45
  • [49] Cutaneous porphyria in a neonate with tyrosinaemia type 1
    Serge Vanden Eijnden
    Denise Blum
    Anne Clercx
    Philippe Goyens
    Corine De Laet
    Esther Vamos
    European Journal of Pediatrics, 2000, 159 : 503 - 506
  • [50] Nitisinone in the Treatment of Hereditary Tyrosinaemia Type 1
    Patrick J. McKiernan
    Drugs, 2006, 66 : 743 - 750